Bull Flag Stocks
BBNX is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
BETA BIONICS INC (BBNX) Stock Price & Overview
NASDAQ:BBNX • US08659B1026
Current stock price
12.27 USD
-0.64 (-4.96%)
At close:
12.3 USD
+0.03 (+0.24%)
After Hours:
The current stock price of BBNX is 12.27 USD. Today BBNX is down by -4.96%. In the past month the price increased by 11.34%. In the past year, price increased by 11.95%.
BBNX Key Statistics
52-Week Range8.8 - 32.71
Current BBNX stock price positioned within its 52-week range.
1-Month Range8.8 - 13.35
Current BBNX stock price positioned within its 1-month range.
- Market Cap
- 546.751M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.94
- Dividend Yield
- N/A
BBNX Stock Performance
Today
-4.96%
1 Week
+3.90%
1 Month
+11.34%
3 Months
-23.12%
Longer-term
6 Months -41.43%
1 Year +11.95%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
BBNX Stock Chart
BBNX Stock Screens
BBNX currently appears in the following ChartMill screener lists.
BBNX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BBNX. When comparing the yearly performance of all stocks, BBNX is a bad performer in the overall market: 76.85% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
BBNX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BBNX. No worries on liquidiy or solvency for BBNX as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BBNX Earnings
On April 21, 2026 BBNX reported an EPS of -0.49 and a revenue of 27.63M. The company beat EPS expectations (1.68% surprise) and beat revenue expectations (0.46% surprise).
Next Earnings DateN/A
Last Earnings DateApr 21, 2026
PeriodQ1 / 2026
EPS Reported-$0.49
Revenue Reported27.63M
EPS Surprise 1.68%
Revenue Surprise 0.46%
BBNX Forecast & Estimates
18 analysts have analysed BBNX and the average price target is 23.63 USD. This implies a price increase of 92.58% is expected in the next year compared to the current price of 12.27.
For the next year, analysts expect an EPS growth of -0.59% and a revenue growth 34.67% for BBNX
Analysts
Analysts82.22
Price Target23.63 (92.58%)
EPS Next Y-0.59%
Revenue Next Year34.67%
BBNX Groups
Sector & Classification
BBNX Financial Highlights
Over the last trailing twelve months BBNX reported a non-GAAP Earnings per Share(EPS) of -1.94. The EPS decreased by -41.37% compared to the year before.
Income Statements
Revenue(TTM)100.25M
Net Income(TTM)-73.20M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.27% | ||
| ROE | -25.45% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%89.34%
Sales Q2Q%57.15%
EPS 1Y (TTM)-41.37%
Revenue 1Y (TTM)53.94%
BBNX Ownership
Ownership
Inst Owners108.29%
Shares44.56M
Float43.53M
Ins Owners2.39%
Short Float %17.79%
Short Ratio6.59
BBNX Latest News, Press Relases and Analysis
5 hours ago - By: Chartmill
BBNX Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 14.76 | 166.816B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.16 | 165.367B | ||
| SYK | STRYKER CORP | 21.64 | 129.577B | ||
| BSX | BOSTON SCIENTIFIC CORP | 17.07 | 90.642B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.46 | 46.953B | ||
| IDXX | IDEXX LABORATORIES INC | 38.43 | 46.307B | ||
| BDX | BECTON DICKINSON AND CO | 11.48 | 45.171B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.98 | 33.834B | ||
| RMD | RESMED INC | 18.02 | 32.944B | ||
| DXCM | DEXCOM INC | 24.61 | 24.87B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.93 | 18.482B | ||
| PODD | INSULET CORP | 29.66 | 13.912B | ||
| GMED | GLOBUS MEDICAL INC - A | 20.58 | 13.095B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BBNX
Company Profile
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 420 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
Company Info
IPO: 2025-01-30
BETA BIONICS INC
11 Hughes
Irvine CALIFORNIA US
Employees: 422
Phone: 18002462677
BETA BIONICS INC / BBNX FAQ
What does BBNX do?
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 420 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
What is the stock price of BETA BIONICS INC today?
The current stock price of BBNX is 12.27 USD. The price decreased by -4.96% in the last trading session.
Does BETA BIONICS INC pay dividends?
BBNX does not pay a dividend.
How is the ChartMill rating for BETA BIONICS INC?
BBNX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for BETA BIONICS INC?
BETA BIONICS INC (BBNX) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the number of employees for BETA BIONICS INC?
BETA BIONICS INC (BBNX) currently has 422 employees.
What is BETA BIONICS INC worth?
BETA BIONICS INC (BBNX) has a market capitalization of 546.75M USD. This makes BBNX a Small Cap stock.